PL2423228T3 - Przeciwciało zawierające IGG2 mającą wprowadzoną do niej mutację aminokwasową - Google Patents
Przeciwciało zawierające IGG2 mającą wprowadzoną do niej mutację aminokwasowąInfo
- Publication number
- PL2423228T3 PL2423228T3 PL10767069T PL10767069T PL2423228T3 PL 2423228 T3 PL2423228 T3 PL 2423228T3 PL 10767069 T PL10767069 T PL 10767069T PL 10767069 T PL10767069 T PL 10767069T PL 2423228 T3 PL2423228 T3 PL 2423228T3
- Authority
- PL
- Poland
- Prior art keywords
- amino acid
- acid mutation
- antibody containing
- mutation introduced
- containing igg2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17073809P | 2009-04-20 | 2009-04-20 | |
| PCT/JP2010/057027 WO2010123012A1 (ja) | 2009-04-20 | 2010-04-20 | アミノ酸変異が導入されたIgG2を有する抗体 |
| EP10767069.7A EP2423228B1 (en) | 2009-04-20 | 2010-04-20 | Antibody containing igg2 having amino acid mutation introduced therein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2423228T3 true PL2423228T3 (pl) | 2016-06-30 |
Family
ID=43011129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10767069T PL2423228T3 (pl) | 2009-04-20 | 2010-04-20 | Przeciwciało zawierające IGG2 mającą wprowadzoną do niej mutację aminokwasową |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9234044B2 (pl) |
| EP (2) | EP2993188B1 (pl) |
| JP (2) | JP5694921B2 (pl) |
| AU (1) | AU2010240138B9 (pl) |
| CA (1) | CA2759146C (pl) |
| ES (2) | ES2829423T3 (pl) |
| HU (1) | HUE028537T2 (pl) |
| NZ (1) | NZ595825A (pl) |
| PL (1) | PL2423228T3 (pl) |
| PT (1) | PT2423228E (pl) |
| WO (1) | WO2010123012A1 (pl) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009283678B2 (en) * | 2008-08-19 | 2014-01-16 | Glytech, Inc. | Glycoprotein production method and screening method |
| PL2423228T3 (pl) * | 2009-04-20 | 2016-06-30 | Kyowa Hakko Kirin Co Ltd | Przeciwciało zawierające IGG2 mającą wprowadzoną do niej mutację aminokwasową |
| PE20121398A1 (es) | 2009-12-10 | 2012-10-26 | Hoffmann La Roche | Anticuerpos ligantes preferentemente al dominio extracelular 4 de csf1r humano |
| CN102918060B (zh) | 2010-03-05 | 2016-04-06 | 霍夫曼-拉罗奇有限公司 | 抗人csf-1r抗体及其用途 |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| AU2012245205B2 (en) | 2011-04-21 | 2017-06-01 | The Regents Of The University Of California, A California Corporation | Compositions and methods for the treatment of neuromyelitis optica |
| SG194701A1 (en) | 2011-04-29 | 2013-12-30 | Apexigen Inc | Anti-cd40 antibodies and methods of use |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| ES2879552T3 (es) | 2012-10-30 | 2021-11-22 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| RU2670748C9 (ru) | 2013-06-24 | 2018-12-13 | Аблбио | Конъюгаты антител с лекарственными агентами, обладающие улучшенной стабильностью, и их применение |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| CN107172880B (zh) * | 2014-03-24 | 2021-09-28 | 癌症研究技术有限公司 | 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途 |
| WO2017059196A2 (en) | 2015-09-30 | 2017-04-06 | Janssen Biotech, Inc. | Antagonistic antibodies specifically binding human cd40 and methods of use |
| US10513561B2 (en) | 2016-01-12 | 2019-12-24 | National University Corporation Chiba University | Anti-MYL9 antibody |
| CN107474136B (zh) * | 2016-06-08 | 2023-03-07 | 上海交通大学医学院 | 增强激动型抗体活性的抗体重链恒定区序列 |
| RU2756236C2 (ru) | 2016-06-20 | 2021-09-28 | Кимаб Лимитед | PD-L1 специфические антитела |
| EP3504239B1 (en) | 2016-08-25 | 2024-05-29 | F. Hoffmann-La Roche AG | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
| WO2018115051A1 (en) | 2016-12-22 | 2018-06-28 | F. Hoffmann-La Roche Ag | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| EP3585813A1 (en) | 2017-02-22 | 2020-01-01 | Sutro Biopharma, Inc. | Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
| WO2018217944A1 (en) | 2017-05-24 | 2018-11-29 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
| JP2021521804A (ja) | 2018-04-20 | 2021-08-30 | リビジェン バイオファーマ カンパニー リミテッド | 抗ｃｄ４０抗体およびその使用 |
| CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| CN116178544A (zh) * | 2018-09-28 | 2023-05-30 | 礼进生物医药科技（上海）有限公司 | 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途 |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5623587A (en) | 1979-08-03 | 1981-03-05 | Mitsuwa Seiki Co Ltd | Vane type compressor |
| JPS58110600A (ja) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド |
| WO1985003934A1 (en) | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
| JPS60221091A (ja) | 1983-12-21 | 1985-11-05 | Kyowa Hakko Kogyo Co Ltd | 新規プロモ−タ− |
| JP2564268B2 (ja) | 1985-08-28 | 1996-12-18 | 協和醗酵工業株式会社 | 融合抗原ポリペプチド |
| ZA872705B (en) | 1986-04-22 | 1987-10-05 | Immunex Corporation | Human g-csf protein expression |
| JP2958019B2 (ja) | 1988-05-06 | 1999-10-06 | 住友製薬株式会社 | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
| JP2928287B2 (ja) | 1988-09-29 | 1999-08-03 | 協和醗酵工業株式会社 | 新規ポリペプチド |
| JPH02257891A (ja) | 1989-03-31 | 1990-10-18 | Kyowa Hakko Kogyo Co Ltd | 組換え動物細胞による蛋白質の製造 |
| JPH0322979A (ja) | 1989-06-19 | 1991-01-31 | Kyowa Hakko Kogyo Co Ltd | 新規プラスミノーゲン活性化因子 |
| JP3131322B2 (ja) | 1991-12-17 | 2001-01-31 | 協和醗酵工業株式会社 | 新規α２→３シアリルトランスフェラーゼ |
| JP3756946B2 (ja) | 1993-03-29 | 2006-03-22 | 協和醗酵工業株式会社 | α１，３−フコシルトランスフェラーゼ |
| CA2205007C (en) | 1995-09-11 | 2010-12-14 | Masamichi Koike | Antibody against human interleukin-5 receptor .alpha. chain |
| US7247302B1 (en) * | 1996-08-02 | 2007-07-24 | Bristol-Myers Squibb Company | Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| DE60234933D1 (de) | 2001-04-26 | 2010-02-11 | Dako Denmark As | Pan-spezifischer monoklonaler antikörper der gegen glycosiliertes hämoglobin gerichtet ist |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| CN1798767B (zh) * | 2003-04-10 | 2011-02-16 | 晶面生物技术公司 | 通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期 |
| AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
| DK1707627T3 (da) * | 2003-12-25 | 2012-12-17 | Kyowa Hakko Kirin Co Ltd | Antagonistisk anti-CD40-antistofmutant. |
| DE102007010306A1 (de) * | 2007-02-22 | 2008-08-28 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Bispezifisches Fusionsprotein mit therapeutischem und diagnostischem Potenzial |
| PL2423228T3 (pl) * | 2009-04-20 | 2016-06-30 | Kyowa Hakko Kirin Co Ltd | Przeciwciało zawierające IGG2 mającą wprowadzoną do niej mutację aminokwasową |
-
2010
- 2010-04-20 PL PL10767069T patent/PL2423228T3/pl unknown
- 2010-04-20 JP JP2011510330A patent/JP5694921B2/ja active Active
- 2010-04-20 ES ES15190139T patent/ES2829423T3/es active Active
- 2010-04-20 CA CA2759146A patent/CA2759146C/en active Active
- 2010-04-20 HU HUE10767069A patent/HUE028537T2/en unknown
- 2010-04-20 PT PT107670697T patent/PT2423228E/pt unknown
- 2010-04-20 ES ES10767069.7T patent/ES2561081T3/es active Active
- 2010-04-20 AU AU2010240138A patent/AU2010240138B9/en active Active
- 2010-04-20 EP EP15190139.4A patent/EP2993188B1/en active Active
- 2010-04-20 US US13/265,075 patent/US9234044B2/en active Active
- 2010-04-20 NZ NZ595825A patent/NZ595825A/xx unknown
- 2010-04-20 EP EP10767069.7A patent/EP2423228B1/en active Active
- 2010-04-20 WO PCT/JP2010/057027 patent/WO2010123012A1/ja active Application Filing
-
2015
- 2015-02-05 JP JP2015021137A patent/JP6016956B2/ja active Active
- 2015-11-25 US US14/952,419 patent/US9587031B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010240138A1 (en) | 2011-11-10 |
| AU2010240138B9 (en) | 2016-12-15 |
| EP2423228A1 (en) | 2012-02-29 |
| US20160075792A1 (en) | 2016-03-17 |
| US20120087927A1 (en) | 2012-04-12 |
| JPWO2010123012A1 (ja) | 2012-10-25 |
| AU2010240138B2 (en) | 2016-05-12 |
| CA2759146A1 (en) | 2010-10-28 |
| EP2423228B1 (en) | 2015-12-16 |
| EP2993188A1 (en) | 2016-03-09 |
| EP2993188B1 (en) | 2020-08-19 |
| ES2561081T3 (es) | 2016-02-24 |
| CA2759146C (en) | 2017-06-13 |
| WO2010123012A1 (ja) | 2010-10-28 |
| JP6016956B2 (ja) | 2016-10-26 |
| HUE028537T2 (en) | 2016-12-28 |
| PT2423228E (pt) | 2016-02-26 |
| ES2829423T3 (es) | 2021-05-31 |
| EP2423228A4 (en) | 2013-05-08 |
| US9234044B2 (en) | 2016-01-12 |
| US9587031B2 (en) | 2017-03-07 |
| NZ595825A (en) | 2012-10-26 |
| JP5694921B2 (ja) | 2015-04-01 |
| JP2015146805A (ja) | 2015-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2423228E (pt) | Anticorpo contendo igg2 em que foram introduzidas mutações de aminoácidos | |
| EP2481752A4 (en) | MODIFIED CONSTANT ANTIBODY REGIONS | |
| SG10201703707YA (en) | Pharmaceutical formulation containing improved antibody molecules | |
| HK1144948A1 (en) | Humaneered anti-factor antibody | |
| ZA201204266B (en) | Antibody formulation | |
| ZA201106503B (en) | Antibody formulation | |
| ZA201203242B (en) | Antibody formulation | |
| ZA201104545B (en) | Anti-siglec-15 antibody | |
| EP2294227A4 (en) | CONCENTRATION TEST | |
| ZA201101343B (en) | Novel antibody formulation | |
| HK1158233A1 (en) | Mineral amino acid polysaccharide complex | |
| EP2419446A4 (en) | HUMANIZED ANTIBODY COMPOSITIONS AND METHOD FOR BINDING LYSOPHOSPHACIDIC ACID | |
| GB0914826D0 (en) | Assay methods | |
| EP2426149A4 (en) | ANTI-CADHERIN ANTIBODY | |
| PL2414333T3 (pl) | Reagenty i sposoby radioznakowania | |
| EP2283352A4 (en) | Acetaminophen TEST PROCEDURE | |
| IL240134A0 (en) | new proteins | |
| EP2451976A4 (en) | NANO-BIOSENSORS WITH NUCLEIC ACIDS | |
| GB2473934B (en) | Anti-VEEV antibody | |
| GB201013356D0 (en) | Improvements in chemical reactions | |
| TWI367205B (en) | Preparation of paricalcitol | |
| EP2405001A4 (en) | NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERING COMPOSITION | |
| GB0913015D0 (en) | Reagent formulation | |
| GB0916493D0 (en) | Novel assay | |
| GB0911712D0 (en) | Antibody |